Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Maintenance therapy in non-small cell lung cancer.
Genestreti G, Di Battista M, Cavallo G, Bartolotti M, Brandes AA. Genestreti G, et al. Expert Rev Anticancer Ther. 2015;15(7):839-46. doi: 10.1586/14737140.2015.1052410. Epub 2015 May 31. Expert Rev Anticancer Ther. 2015. PMID: 26027675 Review.
Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
Genestreti G, Tiseo M, Kenmotsu H, Kazushige W, Di Battista M, Cavallo G, Carloni F, Bongiovanni A, Burgio MA, Casanova C, Metro G, Scarpi E, Korkmaz T, Selcuk S, Roopa K, Califano R. Genestreti G, et al. Clin Lung Cancer. 2015 Nov;16(6):e223-8. doi: 10.1016/j.cllc.2015.04.006. Epub 2015 Apr 24. Clin Lung Cancer. 2015. PMID: 25983005
Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients.
Gridelli C, Novello S, Zilembo N, Luciani A, Favaretto AG, De Marinis F, Genestreti G, Crinò L, Grossi F, Caffo O, Ferraù F, Cruciani G, Brandes AA, Galetta D, Barni S, Fasola G, Cerea G, Ferrari S, Iannacone C, Ciardiello F. Gridelli C, et al. Among authors: genestreti g. J Thorac Oncol. 2014 May;9(5):733-7. doi: 10.1097/JTO.0000000000000120. J Thorac Oncol. 2014. PMID: 24722160 Free article. Clinical Trial.
The percentage of Epidermal Growth Factor Receptor (EGFR)-mutated neoplastic cells correlates to response to tyrosine kinase inhibitors in lung adenocarcinoma.
de Biase D, Genestreti G, Visani M, Acquaviva G, Di Battista M, Cavallo G, Paccapelo A, Cancellieri A, Trisolini R, Degli Esposti R, Bartolini S, Pession A, Tallini G, Brandes AA. de Biase D, et al. Among authors: genestreti g. PLoS One. 2017 May 16;12(5):e0177822. doi: 10.1371/journal.pone.0177822. eCollection 2017. PLoS One. 2017. PMID: 28520821 Free PMC article.
Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?
Franceschi E, Lamberti G, Paccapelo A, Di Battista M, Genestreti G, Minichillo S, Mura A, Bartolini S, Agati R, Brandes AA. Franceschi E, et al. Among authors: genestreti g. J Neurooncol. 2018 Sep;139(2):383-388. doi: 10.1007/s11060-018-2873-x. Epub 2018 Apr 18. J Neurooncol. 2018. PMID: 29671196
Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial.
Ardizzoni A, Tiseo M, Boni L, Vincent AD, Passalacqua R, Buti S, Amoroso D, Camerini A, Labianca R, Genestreti G, Boni C, Ciuffreda L, Di Costanzo F, de Marinis F, Crinò L, Santo A, Pazzola A, Barbieri F, Zilembo N, Colantonio I, Tibaldi C, Mattioli R, Cafferata MA, Camisa R, Smit EF. Ardizzoni A, et al. Among authors: genestreti g. J Clin Oncol. 2012 Dec 20;30(36):4501-7. doi: 10.1200/JCO.2012.43.6758. Epub 2012 Oct 29. J Clin Oncol. 2012. PMID: 23109689 Clinical Trial.
39 results